采用钆塞酸二钠增强磁共振成像评估化疗药物的肝毒性
回顾性分析129例神经内分泌肿瘤患者共539次钆塞酸二钠增强MRI,用线性混合模型评估肝胆期肝脏相对强化率(RE)与化疗药物肝毒性评分等因素的关系。结果显示已知有肝毒性的化疗药物均对RE有统计学显著负性影响,二分类逻辑回归证实该结果,提示钆塞酸二钠增强MRI可作为影像学肝功能检查评估化疗肝毒性。
要点
- 钆塞酸二钠增强MRI肝胆期肝脏相对强化率(RE)可反映化疗药物对肝功能的负性影响。
- 已知有肝毒性的化疗药物均对肝胆期RE产生统计学显著的负性影响,年龄亦为影响因素。
- 二分类逻辑回归验证肝毒性评分可预测化疗方案对RE的显著影响,即对肝功能的影响。
核心结论
- 钆塞酸二钠增强MRI可作为影像学肝功能检查用于评估神经内分泌肿瘤化疗药物的肝毒性,结果印证了目前所用化疗药物已知的肝毒性程度。
研究设计与样本
- 回顾性分析2014至2018年间接受两次及以上钆塞酸二钠增强MRI、并在该时间段开始时启动化疗的129例神经内分泌肿瘤患者,共539次MRI检查;采用线性混合模型分析肝胆期肝脏相对强化率(RE)与MRI间隔时间、主要化疗方案、前序及后续化疗的肝毒性评分、年龄和性别等固定变量的关系,并用二分类逻辑回归验证肝毒性评分对RE的预测作用。
关键影像表现/征象
- 肝胆期肝脏相对强化率(RE)在已知有肝毒性的化疗药物使用后出现统计学显著的负性影响。
- 线性混合模型分析中,除年龄外,所有已知有肝毒性的化疗药物均为对肝胆期肝脏RE有统计学显著负性影响的因素。
诊断标准与关键数值
- 以肝胆期肝脏相对强化率(RE)作为影像学肝功能指标,评估化疗药物肝毒性对RE的影响。
- 采用肝毒性评分(前序及后续化疗)作为固定变量纳入线性混合模型,并用二分类逻辑回归验证其预测RE显著影响的能力。
临床应用与阅片要点
- 在神经内分泌肿瘤患者化疗随访中,可关注钆塞酸二钠增强MRI肝胆期肝脏相对强化率(RE)的变化,作为评估化疗肝毒性的影像学肝功能指标。
- 解读时应结合患者年龄、主要化疗方案及前序和后续化疗的肝毒性评分综合判断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the hepatotoxicity of different chemotherapeutic agents used to treat neuroendocrine tumours (NETs) with gadoxetic acid-enhanced magnetic resonance imaging (MRI).
MATERIAL AND METHODS: A total of 129 patients with NETs who underwent two or more serial gadoxetic-acid-enhanced MRI examinations between 2014 and 2018 and started chemotherapy in the beginning of that time period were retrospectively analysed. Linear mixed model analysis evaluating relative enhancement (RE) of the liver in the hepatobiliary phase with respect to time between MRI examinations, primary chemotherapy, hepatotoxicity score of preceding and subsequent chemotherapies as well as age and gender as fixed variables was performed. Binary logistic regression was used to verify whether the hepatotoxicity score predicts a significant impact of a chemotherapeutic regimen on RE and hence liver function.
RESULTS: Linear mixed model analysis of a total of 539 MRI examinations identified all chemotherapeutic agents with known hepatoxicity as a factor with a statistically significant negative impact on RE of the liver in gadoxetic-acid-enhanced MRI in addition to age. This result was confirmed by binary logistic regression analysis.
CONCLUSION: Our results confirm that gadoxetic acid-enhanced MRI can be used as an imaging-based liver function test for assessing hepatotoxicity of chemotherapeutic agents used for NETs. The findings underscore the known degrees of hepatotoxicity of the chemotherapeutic agents currently used in the treatment of NETs.
引用
- Theilig D, Elkilany A, Jann H, et al. Evaluating hepatotoxic effects of chemotherapeutic agents with gadoxetic-acid-enhanced magnetic resonance imaging. Eur J Radiol. 2019. PMID: 31926386. doi:10.1016/j.ejrad.2019.108807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。